Want to join the conversation?
$CELG's selling, general and administrative expenses for 2015 increased by 13.7% from 2014. The rise was primarily due to rises in expenses from supporting inflammation and immunology products and product candidates, such as Otezla as well as rises in selling and marketing activities for Revlimid, Otezla and Pomalyst/Imnovid.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)